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ABSTRACT 20 
Background: Only a handful of genetic discovery efforts in apparent treatment resistant 21 
hypertension (aTRH) have been described.  Methods: We conducted a case-control genome-wide 22 
association study (GWAS) of aTRH among persons treated for hypertension, using data from 10 23 
cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA).  Cases were treated 24 
with 3 different antihypertensive medication classes and had blood pressure (BP) above goal 25 
(systolic (SBP)≥140 mm Hg and/or diastolic (DBP)≥90 mm Hg) or 4 or more medication classes 26 
regardless of BP control (nEA =931, nAA= 228).  Both a normotensive control group and a 27 
treatment-responsive control group were considered in separate analyses. Normotensive controls 28 
were untreated (nEA = 14210, nAA= 2480) and had SBP/DBP <140/90 mm Hg.  Treatment-29 
responsive controls (nEA = 5266, nAA= 1817) had BP at goal (<140/90 mm Hg) while treated with 30 
one antihypertensive medication class.  Individual cohorts used logistic regression with adjustment 31 
for age, sex, study site and principal components for ancestry to examine the association of SNPs 32 
with case-control status.  Inverse variance-weighted fixed-effects meta-analyses were carried out 33 
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using METAL.  Results: The known hypertension locus, CASZ1, was a top finding among EAs 1 
(P=1.1*10-8) and in the race-combined analysis (P=1.5*10-9) using the normotensive control group 2 
(rs12046278 OR=0.71[95% CI 0.6-0.8]).  SNPs in this locus were robustly replicated in the 3 
Million Veterans Program (MVP) study in consideration of a treatment-responsive control group.  4 
There were no statistically significant findings for the discovery analyses including treatment-5 
responsive controls.  Conclusion: This genomic discovery effort for aTRH identified CASZ1 as an 6 





Apparent treatment-resistant hypertension (aTRH) is an extreme form of hypertension 12 
(HTN) characterized by the use of 4 or more antihypertensive (AHT) medication classes to achieve 13 
blood pressure (BP) control. The estimated prevalence of aTRH in population-based studies is 14 
between 12-15% among adults with hypertension and higher among clinic-based populations, e.g. 15 
>25% in those with chronic kidney disease (CKD).1, 2 Risk factors for aTRH are increasing age, 16 
obesity, reduced kidney function and African-American race.1 Research shows that individuals 17 
with aTRH are at an increased risk for cardiovascular disease (CVD) events when compared to 18 
individuals with controlled HTN, demonstrating a need to understand the cause of nonresponse in 19 
order to improve BP control.3 We hypothesized that identifying the genetic architecture may shed 20 
light on distinct underlying patho-biology.    21 
Published genetic studies of aTRH have reported limited findings and are lacking in 22 
comparison to hypertension. 4-7  The current study comprises European ancestry (EA) and African 23 
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ancestry (AA) studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology 1 
(CHARGE) consortium, for a case-control study of aTRH that capitalizes on epidemiological data 2 
characterized by deep phenotyping.  Common genetic variants in 931 EA aTRH cases were 3 
compared to 14210 normotensive controls and separately to 5266 treatment-responsive controls, 4 
while 228 AA aTRH cases were compared to 2480 normotensive controls and separately to 1817 5 
treatment-responsive controls.  Results were replicated in an aTRH case-control dataset from the 6 
Million Veterans Program (MVP).   7 
METHODS 8 
Ten studies contributed data on EA participants while 5 studies contributed data on AA 9 
participants (Supplemental File Section 1).  Data on medication use were extracted by medication 10 
inventory, self-report, or computerized databases once for cohorts with cross-sectional data, or at 11 
each BP measurement for those with longitudinal data (Supplementary File Section 1).  AHT 12 
medications counted towards the sum of classes are described in Supplemental Table 1. 13 
Combination products were therapeutically co-classified based on their active ingredients. All 14 
diuretics were counted as one class including potassium sparing diuretics.   15 
Participants with conditions that may lead to secondary forms of hypertension (including 16 
eGFR <30 mL/min/1.73m2 or BMI >40 kg/m2) were excluded. aTRH cases were defined as those 17 
treated with 3 AHT medication classes and BP above goal (systolic BP (SBP)≥140 mm Hg and/or 18 
diastolic BP (DBP)≥90 mm Hg) or 4 or more AHT medication classes regardless of BP control.  19 
aTRH cases fitting the above definition who were not treated by a diuretic were excluded.8 The 20 
analysis included two control groups:  1. Normotensive controls:  participants not hypertensive 21 
and not treated with an AHT medication; and 2. Treatment-responsive controls:  participants who 22 
had BP at goal (<140/90 mm Hg) on treatment with one AHT medication class. Details of the case 23 
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and control definition in cohorts with longitudinal data are described in Supplementary File 1 
Section 1.   2 
Genome-wide single nucleotide polymorphism (SNP) genotyping was performed within 3 
each study using commercial genotyping arrays (Supplementary File Table 2). Cohorts most 4 
commonly imputed to the 1000 genomes version 3 reference panel.  After imputation cohorts 5 
filtered out SNPs with imputation quality score <0.3.  SNPs with MAF <5% and which were not 6 
represented in two or more cohorts were filtered out at the meta-analysis stage.   7 
Statistical Analysis 8 
Logistic regression models or generalized estimating equations were used for case-control 9 
association analysis (Supplementary File Table 3).  The variable of interest was SNP dosage of the 10 
effect allele.  Models were adjusted for age, sex and study-specific covariates (e.g., study site, 11 
principal components for ancestry and, if applicable, exchangeable correlation matrices to account 12 
for family relatedness). For cohorts with longitudinal data, the average age across the visits 13 
included was used as the covariate.  In total, there were four models, one for each control group 14 
and one for each ancestry grouping.  Inverse variance-weighted, fixed-effects meta-analysis was 15 
performed for each of the four strata, using METAL software 16 
(www.sph.umich.edu/csg/abecasis/metal/). Statistical heterogeneity across studies was evaluated 17 
using Cochran's χ2 test (Q-test). P-values <5×10−8 indicated genome-wide significant results.  18 
Results of the race-stratified analyses from METAL were then combined using a similar approach 19 
(one meta-analysis per control group).  Linkage disequilibrium (LD) was evaluated using the 20 
rAggr tool (http://raggr.usc.edu/). Regional plots were created using Locus Zoom with a window 21 
of 500kb (v0.4.8).9  In a sensitivity analysis of top SNP results we conducted a meta-analysis that 22 




We sought replication in non-Hispanic EA (78%) and AA (22%) MVP participants 2 
(Supplemental File Section 1). 10, 11  Participants with eGFR ≥60 ml/min/1.73m2 were included. 3 
Total numbers of samples across ethnicities included 16,833 cases (11762 EAs and 5071 AAs) 4 
and 53,931 controls (42850 EAs and 11081 AAs).  Cases were defined using the same definition 5 
as the discovery analysis. Controls were patients who achieved BP control (<140/90 mmHg) on 6 
one or two medication classes. Case-control status was regressed onto additively coded 7 
genotypes imputed to 1000 Genomes phase 3 version 5, adjusting for age, age2, sex, body mass 8 
index, and 10 principal components within ethnicity using SNPTEST v2.54. Genotyping, quality 9 
control (QC), and imputation procedures have been described 10.   10 
 11 
RESULTS 12 
Overall EA and AA cases were older than controls and more likely male (Supplemental 13 
Tables 4a and 4b).  The average number of AHT medication classes for EA cases ranged from 3.2 14 
to 3.8 and from 3.3 to 3.9 for AAs.   Across the individual cohort GWAS analyses, there was not 15 
excessive evidence for the deviation of P-values from their expected values (Supplementary File 16 
Table 5). Manhattan plots and QQ plots for each discovery meta-analysis are presented in 17 
Supplemental Figures 1a-d and 2a-d for the comparison of AA cases to AA normotensive controls, 18 
EA cases to EA normotensive controls, AA cases to AA treatment-responsive controls and EA 19 
cases to EA treatment-responsive controls, respectively.   Meta-analysis corrected inflation that 20 
existed in the cohort-specific analyses. 21 
The top 5 results for each case-control model are presented in Table 1.  When comparing 22 
aTRH cases to normotensive controls, the top finding for AAs was rs76967376 intronic to myosin-23 
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Vb (MYO5B).  At that SNP, the direction of effect was consistent across each of the 5 cohorts and 1 
the odds of being a case were 2.65 [95% CI 1.9-3.8] times higher among those with the A allele 2 
versus the C allele.  Among EAs, the top findings for the normotensive control comparison were 3 
intronic to castor zinc finger 1 (CASZ1).   In the race-combined analysis CASZ1 rs12046278 T 4 
carriers were less likely to be a case (P=1.5*10-9, OR=0.71[95% CI 0.63-0.80]).  Another SNP 5 
within 3500 bp to DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) was associated with 6 
aTRH (P=4.9*10-8) in the race-combined analysis using normotensive controls.  Regional plots 7 
(Supplemental Figures 3-5) for rs76967376 (MYO5B), rs12046278 (CASZ1) and rs11674660 (near 8 
DNMT3A) display linkage disequilibrium support for these top findings.  Results of the race-9 
combined analysis are presented in Supplemental File Table 6 and Supplemental Figure 6.   10 
When comparing aTRH cases to treatment-responsive controls no SNP was statistically 11 
significant after correcting for multiple testing in either racial strata.  Race-combined analysis did 12 
not increase the significance of top hits.  In the sensitivity analysis limiting contributing cohorts to 13 
those with >50 cases results were generally consistent with the main findings in Table 1 14 
(Supplemental Table 7). 15 
The MVP cases in the replication study were older (63±9 vs 62±10 years for EAs and 58±9 16 
vs. 56±10 years for AAs) and had slightly higher BMI compared to the treatment-responsive 17 
controls.  Results for AAs as well as the EAs for the treatment-responsive control group were not 18 
replicated in the MVP.  However, results from the EA discovery for the normotensive control 19 
group were robustly replicated with the same direction of effect for SNPs in CASZ1 (P<5*10-8) 20 
and the direction of association for rs11674660 intergenic to DNMT3A, DTNB was consistent in 21 





While the genetics of BP and essential hypertension have been extensively investigated, 1 
few genetic studies have explored genes associated with less common and more severe aTRH. 2 
Using data available from observational epidemiological cohort studies, the current meta-GWAS 3 
study examined SNPs associated with aTRH in EA and AA cases with respect to two different 4 
control sets.  Our study confirmed the known BP locus, CASZ1, as being robustly associated with 5 
aTRH in the discovery and replication dataset.  Other notable findings, MYO5B and 6 
DMNT3A/DTNB, warrant additional replication efforts.   7 
To our knowledge our top finding in the AA strata (rs76967376 in MYO5B involved in cell 8 
trafficking and plasma membrane recycling) has been associated with lipid levels in previous 9 
GWAS, but has not been associated with hypertension. The nearest published BP locus (rs745821) 10 
is in the MAK4 gene (~505kb in distance) and is not in LD with our finding (r2 <0.01).12 At least 11 
one animal model has reported MYO5B may regulate an atrial voltage-gated potassium channel 12 
(Kv1.5) important for cardiac excitability.13 This result was not replicated in the MVP aTRH case-13 
control dataset. Future studies may still be warranted given the differences in the replication dataset 14 
that used treatment-responsive controls with eGFR ≥60 ml/min/1.73m2.  The top finding among 15 
EAs was the known hypertension locus CASZ1, a zinc finger transcription factor which plays a 16 
key role in cardiac development and postnatal adaptation.14 The gene has been previously 17 
associated with BP and hypertension in Asian ancestry and EA populations.15-17   The biological 18 
role of CASZ1 in aTRH needs additional investigation but may be related to expression changes in 19 
genes that regulate blood pressure or AHT response.18  Taken together the significant results from 20 
the discovery and replication analysis suggest CASZ1 is an aTRH locus among EAs.  The result 21 
for the top SNP was consistent but marginally significant for AAs in CHARGE (OR=0.69[95% 22 
CI 0.48-0.99];P=0.04 for the T allele).  Rs880315 in CASZ1 from Table 1 was marginally 23 
10 
 
significant in MVP blacks (OR=1.09[95% CI 1.03-1.15];P=0.008 for the C allele).  Loci near 1 
DMNT3A/DTNB on chromosome 2 have been identified in a recent BP GWAS study (~300 kb 2 
downstream of ADCY3) though rs11674660 from our study and previously published ADCY3 3 
rs55701159 are not in LD (r2<0.01).12 DMNT3A is causal for clonal hematopoiesis of 4 
indeterminate potential (CHIP), and mutations in DMNT3A have been associated with coronary 5 
heart disease.19  The isoprenylcysteine carboxyl methyltransferase (ICMT) locus was the only gene 6 
near a previously identified HTN gene (~15kb downstream of RNF207 rs709209) 20 that we report 7 
on for the treatment-responsive control group.  The SNP rs11674660 near DMNT3A/DTNB and 8 
rs146183009 in ICMT were not replicated in the MVP.   9 
We also compared our results with published GWAS studies.5, 6  In the electronic MEdical 10 
Records & GEnomics study among 3006 cases and 876 treatment-responsive controls there were 11 
no statistically significant findings.  In the INternational VErapamil SR Trandolapril STudy 12 
GENEtic Substudy, a SNP (rs12817819) in ATPase Plasma Membrane Ca2+ Transporting 1 13 
(ATP2B1) was associated with aTRH  in EAs and Hispanics.  In our data, SNPs in ATP2B1 were 14 
most strongly associated with aTRH when cases were compared to normotensive controls [AAs 15 
rs58302337 (P=0.001), rs12580678 (P=0.004); EAs rs1401982 (P=0.006)] versus treatment 16 
responsive controls [AAs rs152754 (P=0.01); EAs  rs34205054 (P=0.006)].    Differences between 17 
these studies and our own include the use of clinical rather than observational populations and the 18 
consideration of only controlled hypertensive patients as controls.   19 
  Strengths of the current study include collaboration among well-characterized CVD 20 
cohorts for which BP measurement and the recording of AHT information was a focus. Further, 21 
we replicated our findings in a large dataset with comparable ethnic groups.  However, aTRH is 22 
complex and our study had several weaknesses including lack of information on white coat 23 
11 
 
hypertension, adherence information, and medication dosage data which may contribute to 1 
phenotypic misclassification which could dilute our results.  We were unable to distinguish AHT 2 
use for conditions other than hypertension such as glaucoma.  Other limitations included 3 
heterogeneity among study populations regarding phenotypic focus (e.g. obesity and CVD) and 4 
different methods for the measurement of BP.  Finally, the case-control group available for the 5 
replication analysis was not identical to our discovery dataset.   6 
Despite being common among persons with hypertension, little is known about the genetic 7 
etiology of aTRH.  In this discovery and replication effort the main finding included a transcription 8 
factor and known hypertension locus involved in cardiac development (CASZ1).  MYO5B and 9 
DMNT3A/DTNB were biologically interesting cardiovascular candidates that were not replicated 10 
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